| Business Summary | | Biora
AB
develops,
manufactures,
markets
and
sells
products
primarily
for
treatment
of
diseases
in
the
mouth.
During
2000,
Biora
continued
to
grow
the
market
penetration
in
North
America,
Europe
and
Japan.
However,
in
November
2000,
Seikagaku
Corporation,
Biora's
marketing
and
sales
partner
in
Japan,
recalled
all
deliveries
of
Emdogain,
the
Company's
prinicpal
product,
to
comply
with
the
registration
authority's
guidelines,
which
required
the
same
changes
to
be
made
to
the
production
process
for
deliveries
to
Japan
as
had
previously
been
implemented
for
other
markets.
In
the
marketing
and
operational
areas,
Biora
had,
by
the
end
of
2000,
launched
Emdogain
in
approximately
30
countries. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Biora
AB
develops,
manufactures,
markets
and
sells
products
to
dentists
and
dental
hygienists
for
the
treatment
of
periodontal
disease
and
for
use
in
oral
surgery.
For
the
six
months
ended
6/30/01,
net
sales
rose
28%
to
SEK55.8
million.
Net
loss
fell
61%
to
SEK14.8
million.
Results
reflect
the
introduction
of
Emdogain
in
the
U.S.,
the
German
reorganization,
higher
gross
margins,
xerostomia
license
agreement
income
of
SEK3M
and
the
absence
of
SEK5.3
million
in
development
cost
amortization. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Per Wahlstrom, 53 | Chairman | Rickard Soderberg, 42 | Pres,
CEO | Anders Agering, 49 | Exec.
VP and CFO and Production | Helen Svahnqvist, 33 | VP
of International Marketing and Sales | Tommie Johansson | VP,
Corp. Communications and Investor Relations |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|